US 12,139,723 B2
Neural cell extracellular vesicles
Steven L. Stice, Athens, GA (US); Robin Lynn Webb, Winterville, GA (US); and Tracey A. Stice, Athens, GA (US)
Assigned to UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US); and ARUNA BIO, INC., Athens, GA (US)
Filed by University of Georgia Research Foundation, Inc., Athens, GA (US); and Aruna Bio, Inc., Athens, GA (US)
Filed on Apr. 23, 2021, as Appl. No. 17/238,760.
Application 17/238,760 is a continuation of application No. 16/414,576, filed on May 16, 2019, granted, now 11,111,475.
Application 16/414,576 is a continuation of application No. 15/770,881, granted, now 11,993,787, previously published as PCT/US2016/062245, filed on Nov. 16, 2016.
Claims priority of provisional application 62/256,823, filed on Nov. 18, 2015.
Prior Publication US 2022/0356444 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/12 (2015.01); A61K 9/51 (2006.01); A61K 35/30 (2015.01); A61K 35/545 (2015.01); A61P 25/28 (2006.01); C12N 5/079 (2010.01); C12N 5/0793 (2010.01); C12N 5/0797 (2010.01); A61K 9/50 (2006.01); G01N 33/569 (2006.01)
CPC C12N 5/0619 (2013.01) [A61K 9/5176 (2013.01); A61K 35/12 (2013.01); A61K 35/545 (2013.01); C12N 5/0622 (2013.01); C12N 5/0623 (2013.01); A61K 9/5068 (2013.01); A61K 35/30 (2013.01); A61P 25/28 (2018.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2533/30 (2013.01); G01N 33/56966 (2013.01)] 26 Claims
 
1. A method of reducing inflammation in the brain of a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising isolated extracellular vesicles (EVs) derived from non-transformed human neural progenitor cells that are capable of differentiating into neurons, astrocytes and oligodendrocytes in vitro, wherein the EVs are produced from neural progenitor cells derived in vitro from pluripotent stem cells, or from neural cells derived in vitro from the neural progenitor cells or the pluripotent stem cells,
and wherein the EVs comprise one or more of melanoma-associated chondroitin sulfate proteoglycan (MCSP), pentraxin-3 (PTX3), angiopoietin-1, insulin-like growth factor-binding protein 2 (IGFBP2), macrophage colony-stimulating factor, and ecto-5′-nucleotidase (NT5E).